Category: Press Releases

Press Releases

BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum

Apr 28, 2026

VANCOUVER, BC / ACCESS Newswire / April 28, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is...

Continue Reading

Press Releases

BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)

Apr 14, 2026

VANCOUVER, BC / ACCESS Newswire / April 14, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is...

Continue Reading

Press Releases

BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries

Apr 7, 2026

VANCOUVER, BC / ACCESS Newswire / April 7, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is...

Continue Reading

Press Releases

BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy

Mar 30, 2026

VANCOUVER, BC / ACCESS Newswire / March 30, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is...

Continue Reading

Press Releases

BioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform

Mar 24, 2026

VANCOUVER, BC / ACCESS Newswire / March 24, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is...

Continue Reading

Press Releases

BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe

Mar 17, 2026

VANCOUVER, BC / ACCESS Newswire / March 17, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is...

Continue Reading

Press Releases

BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis

Feb 17, 2026

VANCOUVER, BC / ACCESS Newswire / February 17, 2026 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug...

Continue Reading

Press Releases

BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery

Feb 5, 2026

VANCOUVER, BC / ACCESS Newswire / February 5, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, today...

Continue Reading

Press Releases

BioNxt Accelerates ODF for Multiple Sclerosis Toward Human Clinical Study with >40% Bioavailability Improvement and Myasthenia Gravis Expansion

Jan 26, 2026

VANCOUVER, BC / ACCESS Newswire / January 26, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is...

Continue Reading

Press Releases

BioNxt Reports Final Preclinical Results Demonstrating Approximately 40% Higher Cladribine Delivery for the Treatment Multiple Sclerosis (MS)

Jan 21, 2026

VANCOUVER, BC / ACCESS Newswire / January 21, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report final results from a preclinical pig...

Continue Reading

Press Releases

BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF

Jan 19, 2026

VANCOUVER, BC / ACCESS Newswire / January 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is...

Continue Reading

Press Releases

Over 40% of Adults Struggle to Swallow Pills – BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies

Dec 17, 2025

VANCOUVER, BC / ACCESS Newswire / December 17, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is...

Continue Reading